(1) Chemotherapy plus ICI as first‐line therapy might not yield a better survival benefit than chemotherapy alone or in combination with angiogenesis inhibitors in advanced NSCLC with EGFR ex20ins. This evidence concerns the gene EGFR and non-small cell lung carcinoma.